行情

SGEN

SGEN

Seattle Genetics
NASDAQ

实时行情|Nasdaq Last Sale

72.83
+0.88
+1.22%
盘后: 72.83 0 0.00% 16:12 09/18 EDT
开盘
72.23
昨收
71.95
最高
73.04
最低
71.70
成交量
54.28万
成交额
--
52周最高
84.37
52周最低
50.71
市值
122.92亿
市盈率(TTM)
-41.7388
分时
5日
1月
3月
1年
5年

分析师评级

17位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

SGEN 新闻

  • Seattle Genetics Announces Presentations of New Clinical Data from Multiple Studies of Novel Targeted Therapies at the European Society for Medical Oncology (ESMO) 2019 Congress
  • Business Wire.1天前
  • Seattle Genetics Highlights Presentations Of New Clinical Data From Multiple Studies Of Novel Targeted Therapies At ESMO Congress
  • Benzinga.1天前
  • Seattle Genetics' Enfortumab Vedotin BLA Gets Priority Review
  • Zacks.com.1天前
  • FDA grants accelerated review for Seattle Genetics ADC for urothelial cancer
  • seekingalpha.2天前

更多

所属板块

生物技术和医学研究
-0.89%
制药与医学研究
-0.16%

热门股票

名称
价格
涨跌幅

SGEN 简况

Seattle Genetics, Inc. is a biotechnology company focused on the development and commercialization of therapies for the treatment of cancer. The Company is engaged in the development and sale of pharmaceutical products on its own behalf or in collaboration with others. The Company's marketed product ADCETRIS, or brentuximab vedotin, is an antibody-drug conjugate (ADC). In addition to ADCETRIS, the Company's pipeline includes other clinical-stage ADC programs, such as ASG-22ME, SGN-LIV1A, SGN-CD19A, SGN-CD19B, SGN-CD123A, SGN-352A, and ASG-15ME, as well as two immuno-oncology agents, SEA-CD40, which is based on its sugar-engineered antibody (SEA) technology, and SGN-2FF, which is a small molecule. It also has multiple preclinical and research-stage programs that employ its technologies, including SGN-CD48A and a preclinical ADC. ADCETRIS is an ADC comprising an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent.
展开

Webull提供Seattle Genetics, Inc.的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。